Eli Lilly and Company has launched Employer Connect, a new platform designed to give employers a direct pathway to offer coverage for the weight-loss medication Zepbound outside traditional pharmacy benefit structures.
Through the platform, employers can work with independent program administrators—such as Calibrate Health, Teladoc Health, GoodRx, and Cost Plus Drugs—to design obesity treatment benefits for employees.
Under the program, Zepbound will be available at a list price of $449 per month for all doses of the KwikPen, with dispensing handled through a pharmacy network that includes HealthDyne and CenterWell Pharmacy. Final costs for employers and employees may vary depending on dispensing fees and administrative program costs.
Resource: Eli Lilly launches direct-to-employer GLP-1 platform